These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
758 related articles for article (PubMed ID: 30203184)
1. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer. Gadgeel SM Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184 [TBL] [Abstract][Full Text] [Related]
2. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer. Mak DWS; Li S; Minchom A Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197 [TBL] [Abstract][Full Text] [Related]
3. Unravelling the biology of SCLC: implications for therapy. Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531 [TBL] [Abstract][Full Text] [Related]
4. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer]. Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582 [TBL] [Abstract][Full Text] [Related]
5. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870 [TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. Xiong J; Barayan R; Louie AV; Lok BH Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883 [TBL] [Abstract][Full Text] [Related]
7. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500 [No Abstract] [Full Text] [Related]
8. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy. Ragavan M; Das M Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742 [TBL] [Abstract][Full Text] [Related]
9. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727 [TBL] [Abstract][Full Text] [Related]
10. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer. Konala VM; Madhira BR; Ashraf S; Graziano S Oncology; 2020; 98(11):749-754. PubMed ID: 32663833 [TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666 [TBL] [Abstract][Full Text] [Related]
12. Targeting DNA damage in SCLC. Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F Lung Cancer; 2017 Dec; 114():12-22. PubMed ID: 29173760 [TBL] [Abstract][Full Text] [Related]
13. Personalized Therapy of Small Cell Lung Cancer. Schneider BJ; Kalemkerian GP Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804 [TBL] [Abstract][Full Text] [Related]
15. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362 [TBL] [Abstract][Full Text] [Related]
16. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer]. Huang B; Duan Y Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):239-244. PubMed ID: 31014443 [TBL] [Abstract][Full Text] [Related]
17. [Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer]. Zhang SY; Wang Y Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):98-103. PubMed ID: 33472320 [TBL] [Abstract][Full Text] [Related]
18. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Meder L; Schuldt P; Thelen M; Schmitt A; Dietlein F; Klein S; Borchmann S; Wennhold K; Vlasic I; Oberbeck S; Riedel R; Florin A; Golfmann K; Schlößer HA; Odenthal M; Buettner R; Wolf J; Hallek M; Herling M; von Bergwelt-Baildon M; Reinhardt HC; Ullrich RT Cancer Res; 2018 Aug; 78(15):4270-4281. PubMed ID: 29776963 [TBL] [Abstract][Full Text] [Related]
19. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]